Rock Springs Capital Management’s Design Therapeutics DSGN Stock Holding History

Rock Springs Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-460,391	Closed	-$1.09M	–	108
2023 Q3	$1.09M	Hold	460,391	–	–	0.03%	108
2023 Q2	$2.9M	Hold	460,391	–	–	0.07%	99
2023 Q1	$2.66M	Hold	460,391	–	–	0.06%	101
2022 Q4	$4.72M	Hold	460,391	–	–	0.11%	89
2022 Q3	$7.7M	Hold	460,391	–	–	0.2%	88
2022 Q2	$6.45M	Buy	460,391 +114,794	+33%	+$1.55M	0.19%	91
2022 Q1	$5.58M	Buy	345,597 +10,350	+3%	+$159K	0.14%	100
2021 Q4	$7.18M	Buy	335,247 +1,197	+0.4%	+$20.6K	0.17%	107
2021 Q3	$4.91M	Buy	334,050 +2,000	+0.6%	+$33.3K	0.1%	127
2021 Q2	$6.6M	Buy	332,050 +4,800	+1%	+$121K	0.13%	130
2021 Q1	$9.79M	Buy	+327,250	New	+$11M	0.21%	118

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rock Springs Capital Management's DSGN Position: Q4 2023 in Review

Rock Springs Capital Management sold out of Design Therapeutics (DSGN) in Q4 2023, closing a stake of 460,391 shares — an estimated $1.09M sold.

Rock Springs Capital Management first reported a position in DSGN in Q1 2021 and held it in 11 quarters. The position peaked at $9.79M in Q1 2021. 88 funds tracked by Wall St. Rank hold DSGN as of Q4 2023.

Rock Springs Capital Management reported no remaining Design Therapeutics position as of Q4 2023 after selling out during the quarter.
Rock Springs Capital Management sold 460,391 Design Therapeutics shares in Q4 2023, an estimated $1.09M.
Rock Springs Capital Management first reported a position in Design Therapeutics in Q1 2021 and held it in 11 quarters.
Rock Springs Capital Management's Design Therapeutics position peaked at $9.79M in Q1 2021.
88 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2023.

Based on Rock Springs Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.